May 6, 2014:
May 6, 2014: Nymox announced today new positive outcome results from the Company’s ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer.
April 30, 2014:
April 30, 2014: Nymox is pleased to report top-line results from the company’s 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients with low grade localized (T1c)prostate cancer treated with a single injection of NX-1207.
March 14, 2014:
March 14, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ending December 31, 2013.
April 16, 2013:
April 16, 2013: Nymox reported today positive new study findings which have demonstrated that the Company’s NX-1207 Phase 3 treatment for benign prostatic hyperplasia (BPH or prostatic enlargement) has no detectable effect on key male structures involved in sexual function. This study has provided new data which offers further scientific support of highly selective sparing of prostatic nerves after NX-1207 treatment.
March 27, 2013:
March 27, 2013: Nymox reported today that the Company’s FDA cleared NicAlert™ product continues to achieve widespread acceptance around the world as an important tool in tobacco-related research studies and programs in a broad range of healthcare areas.
February 19, 2013:
February 19, 2013: Nymox is pleased to announce its lead drug candidate, NX-1207, has not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug.
December 16, 2010:
December 16, 2010: Recordati (Milan: REC.MI) and Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today the signing of a European licensing agreement for the development and commercialization of NX-1207.